|
|
|
Volumn 1, Issue 1, 1996, Pages 6-8
|
|
A bend in the road--implications of ACTG 175 and Delta trials.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
DIDANOSINE;
ZALCITABINE;
ZIDOVUDINE;
AUSTRALIA;
CLINICAL TRIAL;
COMPARATIVE STUDY;
DRUG COMBINATION;
EDITORIAL;
EUROPE;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
SURVIVAL;
UNITED STATES;
ANTI-HIV AGENTS;
AUSTRALIA;
CLINICAL TRIALS;
DIDANOSINE;
DRUG THERAPY, COMBINATION;
EUROPE;
HIV INFECTIONS;
HIV-1;
HUMANS;
SURVIVAL ANALYSIS;
UNITED STATES;
ZALCITABINE;
ZIDOVUDINE;
|
|
EID: 0029677212
PISSN: 13596535
EISSN: None
Source Type: Journal
DOI: None Document Type: Editorial |
|
Times cited : (4)
|
|
References (0)
|
